These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

128 related articles for article (PubMed ID: 18559270)

  • 1. A structural view of the inactivation of the SARS coronavirus main proteinase by benzotriazole esters.
    Verschueren KH; Pumpor K; Anemüller S; Chen S; Mesters JR; Hilgenfeld R
    Chem Biol; 2008 Jun; 15(6):597-606. PubMed ID: 18559270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Structure-based virtual screening against SARS-3CL(pro) to identify novel non-peptidic hits.
    Mukherjee P; Desai P; Ross L; White EL; Avery MA
    Bioorg Med Chem; 2008 Apr; 16(7):4138-49. PubMed ID: 18343121
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Structure of the SARS coronavirus main proteinase as an active C2 crystallographic dimer.
    Xu T; Ooi A; Lee HC; Wilmouth R; Liu DX; Lescar J
    Acta Crystallogr Sect F Struct Biol Cryst Commun; 2005 Nov; 61(Pt 11):964-6. PubMed ID: 16511208
    [TBL] [Abstract][Full Text] [Related]  

  • 4. X-Ray Structure and Inhibition of 3C-like Protease from Porcine Epidemic Diarrhea Virus.
    St John SE; Anson BJ; Mesecar AD
    Sci Rep; 2016 May; 6():25961. PubMed ID: 27173881
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Structure-guided design and optimization of dipeptidyl inhibitors of norovirus 3CL protease. Structure-activity relationships and biochemical, X-ray crystallographic, cell-based, and in vivo studies.
    Galasiti Kankanamalage AC; Kim Y; Weerawarna PM; Uy RA; Damalanka VC; Mandadapu SR; Alliston KR; Mehzabeen N; Battaile KP; Lovell S; Chang KO; Groutas WC
    J Med Chem; 2015 Apr; 58(7):3144-55. PubMed ID: 25761614
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A simple procedure for the derivation of electron density based surfaces of drug-receptor complexes from a combination of X-ray data and theoretical calculations.
    Mebs S; Lüth A; Luger P
    Bioorg Med Chem; 2010 Aug; 18(16):5965-74. PubMed ID: 20634077
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Structure and function of SARS-CoV and SARS-CoV-2 main proteases and their inhibition: A comprehensive review.
    Li X; Song Y
    Eur J Med Chem; 2023 Nov; 260():115772. PubMed ID: 37659195
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Lessons Learnt from COVID-19: Computational Strategies for Facing Present and Future Pandemics.
    Pavan M; Moro S
    Int J Mol Sci; 2023 Feb; 24(5):. PubMed ID: 36901832
    [TBL] [Abstract][Full Text] [Related]  

  • 9. From Repurposing to Redesign: Optimization of Boceprevir to Highly Potent Inhibitors of the SARS-CoV-2 Main Protease.
    Göhl M; Zhang L; El Kilani H; Sun X; Zhang K; Brönstrup M; Hilgenfeld R
    Molecules; 2022 Jul; 27(13):. PubMed ID: 35807537
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Ligand-based design, molecular dynamics and ADMET studies of suggested SARS-CoV-2 M
    Mohamed NM; Ali EMH; AboulMagd AM
    RSC Adv; 2021 Jan; 11(8):4523-4538. PubMed ID: 35747608
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Targeting severe acute respiratory syndrome-coronavirus (SARS-CoV-1) with structurally diverse inhibitors: a comprehensive review.
    Hosseini-Zare MS; Thilagavathi R; Selvam C
    RSC Adv; 2020 Jul; 10(47):28287-28299. PubMed ID: 35519094
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Evaluation of SARS-CoV-2 Main Protease Inhibitors Using a Novel Cell-Based Assay.
    Cao W; Cho CD; Geng ZZ; Shaabani N; Ma XR; Vatansever EC; Alugubelli YR; Ma Y; Chaki SP; Ellenburg WH; Yang KS; Qiao Y; Allen R; Neuman BW; Ji H; Xu S; Liu WR
    ACS Cent Sci; 2022 Feb; 8(2):192-204. PubMed ID: 35229034
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Perspectives on SARS-CoV-2 Main Protease Inhibitors.
    Gao K; Wang R; Chen J; Tepe JJ; Huang F; Wei GW
    J Med Chem; 2021 Dec; 64(23):16922-16955. PubMed ID: 34798775
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Indole Chloropyridinyl Ester-Derived SARS-CoV-2 3CLpro Inhibitors: Enzyme Inhibition, Antiviral Efficacy, Structure-Activity Relationship, and X-ray Structural Studies.
    Ghosh AK; Raghavaiah J; Shahabi D; Yadav M; Anson BJ; Lendy EK; Hattori SI; Higashi-Kuwata N; Mitsuya H; Mesecar AD
    J Med Chem; 2021 Oct; 64(19):14702-14714. PubMed ID: 34528437
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Multi-omics data integration and network-based analysis drives a multiplex drug repurposing approach to a shortlist of candidate drugs against COVID-19.
    Tomazou M; Bourdakou MM; Minadakis G; Zachariou M; Oulas A; Karatzas E; Loizidou EM; Kakouri AC; Christodoulou CC; Savva K; Zanti M; Onisiforou A; Afxenti S; Richter J; Christodoulou CG; Kyprianou T; Kolios G; Dietis N; Spyrou GM
    Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34009288
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Lead compounds for the development of SARS-CoV-2 3CL protease inhibitors.
    Iketani S; Forouhar F; Liu H; Hong SJ; Lin FY; Nair MS; Zask A; Huang Y; Xing L; Stockwell BR; Chavez A; Ho DD
    Nat Commun; 2021 Apr; 12(1):2016. PubMed ID: 33795671
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Innate immune evasion mediated by picornaviral 3C protease: Possible lessons for coronaviral 3C-like protease?
    Ng CS; Stobart CC; Luo H
    Rev Med Virol; 2021 Sep; 31(5):1-22. PubMed ID: 33624382
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A small molecule compound with an indole moiety inhibits the main protease of SARS-CoV-2 and blocks virus replication.
    Hattori SI; Higashi-Kuwata N; Hayashi H; Allu SR; Raghavaiah J; Bulut H; Das D; Anson BJ; Lendy EK; Takamatsu Y; Takamune N; Kishimoto N; Murayama K; Hasegawa K; Li M; Davis DA; Kodama EN; Yarchoan R; Wlodawer A; Misumi S; Mesecar AD; Ghosh AK; Mitsuya H
    Nat Commun; 2021 Jan; 12(1):668. PubMed ID: 33510133
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Protein structural heterogeneity: A hypothesis for the basis of proteolytic recognition by the main protease of SARS-CoV and SARS-CoV-2.
    Behnam MAM
    Biochimie; 2021 Mar; 182():177-184. PubMed ID: 33484784
    [TBL] [Abstract][Full Text] [Related]  

  • 20. What coronavirus 3C-like protease tells us: From structure, substrate selectivity, to inhibitor design.
    Xiong M; Su H; Zhao W; Xie H; Shao Q; Xu Y
    Med Res Rev; 2021 Jul; 41(4):1965-1998. PubMed ID: 33460213
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.